Chordia Therapeutics (190A) · TargetSoftened
Advance the pipeline as planned and steadily create new drug discovery targets and pipelines
First written in FY2024. 1 of 2 entries say "Softened", first in FY2025. Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Managing Corporate Goals Through R&D Pipeline ProgressA theme 7 companies write about · 0 as a headwind · 6 as a tailwind
Chordia Therapeutics moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Softened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025SoftenedAnnual report
「As the Company is currently concentrating its R&D resources on rogocekib, it is taking a cautious approach to considering new pipelines.」
While the Company aims to advance its existing pipeline and generate new targets and pipelines, it indicated that it is taking a cautious approach to considering new pipelines because resources are currently concentrated on rogocekib. - FY2024First statedAnnual report
「The Company's immediate management objectives are to advance R&D on its pipeline as planned toward the early marketing of anticancer drugs, and to establish a system for consistently identifying new drug discovery targets and generating new pipelines.」
The Company indicated that its management objectives focus on progress in the existing pipeline and the system for generating new pipelines, rather than product sales or ROA and ROE.